Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
Price : $35 *
At a glance
- Drugs Tasadenoturev (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 23 Oct 2017 Status changed from active, no longer recruiting to completed.
- 05 Apr 2017 Results assessing safety, efficacy and prognostic biomarkers of DNX-2401 treatment response, presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 17 Nov 2016 Data from this trial will be presented at the 21st Annual Meeting of the Society for Neuro-Oncology, according to a DNAtrix media release.